Stockscreener 앱 받기
8.13
3.33%
-0.28
시간 외 거래:
7.97
-0.16
-1.97%
전일 마감가:
$8.41
열려 있는:
$8.21
하루 거래량:
1.76M
Relative Volume:
1.69
시가총액:
$742.34M
수익:
$823.60M
순이익/손실:
$-116.00M
주가수익비율:
-6.2538
EPS:
-1.3
순현금흐름:
$-107.30M
1주 성능:
-8.45%
1개월 성능:
-21.98%
6개월 성능:
-69.29%
1년 성능:
-59.79%
1일 변동 폭
$7.88
$8.50
1주일 범위
$7.88
$9.02
52주 변동 폭
$7.88
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
8.13 | 742.34M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
437.91 | 165.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
181.77 | 130.05B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
393.73 | 31.91B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
103.00 | 29.38B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
154.73 | 27.28B | 15.41B | 1.37B | 2.11B | 7.50 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 개시 | Craig Hallum | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Myriad Genetics stock hits 52-week low at $8.44 amid market challenges - Investing.com
10 Analysts Assess Myriad Genetics: What You Need To Know - Benzinga
(MYGN) Technical Data - news.stocktradersdaily.com
Scotiabank cuts Myriad Genetics target to $20, keeps outperform rating By Investing.com - Investing.com Canada
Cancer Biomarkers Market Set to Witness Significant Growth - openPR.com
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? - MSN
Myriad Genetics stock hits 52-week low at $9.36 amid challenges By Investing.com - Investing.com South Africa
Myriad Genetics stock hits 52-week low at $9.36 amid challenges - Investing.com Australia
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Press Release Service: United States Molecular Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent, Qiagen, Myriad Genetics, Abbott, Danaher, BD & CoResearchAndMarkets.co - CRISPR Medicine News
Trend Tracker for (MYGN) - Stock Traders Daily
Global Preventive Healthcare Technologies And Services Market - openPR
The Future of Genetic Testing: Industry Growth, Trends & Key - openPR
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31% - Simply Wall St
Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup - MSN
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Benzinga
Myriad Genetics (MYGN) Stock Jumps on Analyst Upgrade - GuruFocus.com
Myriad Genetics Shares Rise After Upgrade From Piper Sandler -March 12, 2025 at 02:53 pm EDT - Marketscreener.com
Myriad Genetics stock upgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha
Why Are Myriad Genetics (MYGN) Shares Soaring Today - Yahoo Finance
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Medical Equipment Stock Jumps on Upgrade - Schaeffers Research
Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges - TipRanks
Piper Sandler upgrades Myriad to 'overweight' on CEO change - TradingView
Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50 - Marketscreener.com
Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler - TipRanks
Morgan Stanley cuts Myriad Genetics stock target to $16 from $21 - Investing.com Canada
(MYGN) On The My Stocks Page - Stock Traders Daily
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Myriad Genetics at Leerink Global Healthcare Conference: Strategic Growth Amid Challenges - Investing.com Canada
Myriad Genetics stock hits 52-week low at $9.74 amid challenges - Investing.com Canada
Myriad Genetics stock hits 52-week low at $9.74 amid challenges By Investing.com - Investing.com South Africa
Myriad Genetics, Inc. to Host Earnings Call - ACCESS Newswire
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
Piper Sandler Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $11.50 - Defense World
US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results - Yahoo Finance
Analyst Expectations For Myriad Genetics's FutureMyriad Genetics (NASDAQ:MYGN) - Benzinga
Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes - TipRanks
Myriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Lowered to Hold Rating by StockNews.com - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Sets New 12-Month Low on Disappointing Earnings - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Earns "Outperform" Rating from Raymond James - MarketBeat
UBS Group Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
Leerink Partnrs Forecasts Myriad Genetics Q2 Earnings - MarketBeat
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - GlobeNewswire
Myriad Genetics Partners With Gabbi To Offer Breast Cancer Risk Assessment & Care Solution - Nasdaq
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.49%
자본화:
|
볼륨(24시간):